Correlation between symptoms developed after the oral ingestion of 50 g lactose and results of hydrogen breath testing for lactose intolerance 
Introduction
Lactose intolerance is a common condition affecting a large proportion of the world's population 1 . The prevalence of lactose intolerance differs in various parts of the world ranging from 3-8% in the Scandinavian and Northwest Europe population to 50-100% of the Southeast Asian population 2, 3, 4 . In Europe the prevalence increases towards South and East reaching 70% in southern Italy and Turkey
5
. The most common cause of lactose intolerance is lactase deficiency -a decreased production of the enzyme lactase in the small intestinal villi. Lactase deficient individuals are not able to cleave this disaccharide in glucose and galactose and may become symptomatic after the ingestion of lactose. As a consequence, lactose reaches the large intestine where it is metabolized by the colonic flora. The high osmotic load caused by lactose in the small intestine and the bacterial metabolites are considered to play an important role in the genesis of the classic symptoms of lactose intolerance such as diarrhea, bloating, nausea, borborygmi and abdominal pain.
Lactose hydrogen breath test (H2-BT) has been used for more than 30 years to diagnose lactase deficiency in clinical practice 6 . This test exploits the fact that normal colonic flora metabolizes lactose into hydrogen (H 2 ) and short chain fatty acids.
Hydrogen reaches the splanchnic venous circulation by diffusion through the intestinal wall, is transported from here through the portal system to the liver and the systemic circulation and is eventually exhaled through the lungs. The sensitivity and specificity of an increase in H 2 concentration in the exhaled air to diagnose lactose intolerance range from 76-94% and 77-96%, respectively 7 . While the H2-BT is considered the "gold standard" of the non-invasive tests to diagnose lactose intolerance there is limited information on the sensitivity and specificity of symptoms developed in response to the ingestion of a given amount of lactose 8 .
The aim of this study was to evaluate the sensitivity and specificity of symptoms developed after the ingestion of 50g of lactose for a positive H2-BT. We hypothesized an association between the number of symptoms developed after the ingestion of 50g of lactose and a positive hydrogen breath test.
Materials and methods
Data from all patients referred for H2-BT between 1999 and 2005 were collected prospectively. Demographic data included age, gender and country of origin (grouped by "Swiss" vs. "non-Swiss"). They included both the result of the test itself and information on symptom occurrence and severity after lactose ingestion as recorded in a structured questionnaire.
Breath H2 concentration was measured using a H2 breath test device (Stimotron Medizinische Geräte GmbH, Wendelstein, Germany) equipped with an electrochemically working hydrogen cell. The breath analyser is able to detect H2
concentrations in the range of 0-250 parts per million (ppm) with an accuracy of ± 2%
(1ppm at values below 50ppm). The instrument was calibrated using standardized compressed gas with a H2 concentration of 96.8 ppm (Calibration Gas, compressed gas, No. 5, BDL. A/R). Air samples (20 ml each) were insufflated in the H2 breath test device and the H2 concentration was read from a digital panel meter.
Patients underwent the H2-BT after fasting overnight at the Gastrointestinal Function
Unit of the University Hospital of Zurich Patients were asked to be fasting and refrain from smoking for at least 6 hours prior to the test. Furthermore patients were asked to discontinue possible use of antibiotics one week and laxatives one day before the H2BT. Prior to the beginning of the test, two samples of mixed end-expired air were aspirated into a 20ml plastic syringe (Injekt 20ml, Braun) fitted with a three-way stopcock. The sample with the higher amount of H2 was used as baseline value and the test was performed provided both values were below 20ppm. After determining the baseline H2 breath concentration, the subject ingested 50g of lactose dissolved in 300ml of water. Over a 2-3 hour period breath samples were collected as described above at 15 minutes intervals while the patient was in sitting position. At the time of breath sampling patients were asked to rate 5 symptoms (abdominal pain, nausea, bloating, borborygmi and diarrhea) using a 9-point scale (0 -no symptom to 9 -worst symptom severity).
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For each patient we determined the maximal intensity of each of the 5 symptoms as the highest symptom intensity value recorded during the duration of the breath test
The lactose H2-BT was considered positive if the H2 concentration in the exhaled air exceeded 20 ppm above baseline at least twice during the monitoring period 9 . A symptom was considered positive if the patient reported a 2-point or more increase above baseline in the severity of the symptom at least twice.
The data analysis was approved by the ethical committee of the University Hospital of Zurich and of the Canton of Zurich, Switzerland.
Statistical analysis
The Chi-square test was utilized to analyze differences between proportions. 
Intensity of symptoms in patients with positive vs. negative breath tests
Patients with a positive H2-lactose breath test reported higher symptom intensities compared to patients with a negative breath test. The differences in symptom intensity ( Figure 2) 
Discussion
In the present study, we report the sensitivity and specificity of abdominal pain, nausea, bloating, borborygmi and diarrhea developed in response to the ingestion of 50g lactose to identify patients with lactase deficiency as shown by a positive H2-BT.
This information is important since symptoms of lactose intolerance overlap with features of irritable bowel syndrome and, thus, discrimination between these two disease entities may result difficult 10 . We found that bloating had the best sensitivity (71%) and negative predictive value (82%) while diarrhea had the best specificity (90%) and positive predictive value (66%) to identify patients with a positive H2-BT.
Twenty-one percent of patients who developed one symptom after the ingestion of 50g lactose were found to have lactase deficiency based on the results of the lactose H2-BT. Eighty-one percent of patients who developed all 5 symptoms had a positive (abnormal) lactose H2-BT. These data indicate that evaluation of symptoms developed in response to the ingestion of a predefined amount of lactose could represent a simple screening test for lactose intolerance.
In a pragmatic approach we consider that patients who do not develop any symptoms after ingesting 50 grams of lactose do not need to be referred for hydrogen breath testing as (1) the likelihood of the test being positive is around 10% and (2) even in the case of a positive result it would be difficult to justify the clinical benefits of a lactose free diet in the absence of symptoms. At the other end of the spectrum, one might argue that a hydrogen breath testing would not be necessary in patients who
Gelöscht: will develop all 5 symptoms as the likelihood of them having a positive test is high (68-91% depending on demographic background). Recommending these patients to strictly adhere to a lactose-free diet and reevaluate of their symptom pattern after 4 -6 weeks could be tried first. As lactose is used in various processed foods a consultation with a dietician might be necessary in some patients to ensure adherence to a lactose-free diet. Patients with persisting symptoms on a lactose free diet should be examined for other pathologies. In patients improving on a lactose-free diet formal documentation of low lactase activity would be required given the major lifestyle and diet changes implied by a life-long diagnosis of lactose intolerance.
Lactose intolerance testing should be recommended to patients who develop two or three symptoms after the ingestion of 50g lactose as the pretest probability of them having a positive or negative test is in the range of a coin toss. The same applies for patients who develop one or four symptoms after the ingestion of 50g lactose.
Although patients developing one symptom are more likely to be negative and In addition, the authors noted that the peak H2-excretion was higher in patients with higher TSS compared to those with low TSS. Based on these data the authors concluded that gastrointestinal symptoms after 50g lactose challenge are strongly associated with the amount of breath H2
Gelöscht: ¶ Hydrogen breath testing should be recommended to patients who develop two or three symptoms after the ingestion of 50g lactose as the pretest probability of them having a positive or negative test is in the range of a coin toss. The challenging groups of patients are those developing one or four symptoms after the ingestion of 50g lactose. In these patients our current recommendation is that the decision of testing or empirically treating should be left at the discretion of the patient and his or her physician. Costeffectiveness analysis and decision modeling could provide additional information in favor or against these recommendations and help in defining the management of patients suffering one or 4 symptoms after the lactose ingestion test. ¶
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Gelöscht: the excretion. Unfortunately the authors did not provide an additional analysis of individual symptoms.
Suarez et al performed a randomized, double-blind, controlled study comparing symptoms in 30 patients with self-reported severe lactose intolerance 14 . Each patient received 240ml of either 2% fat milk containing on average 12.1g lactose or 2% fat lactose-hydrolyzed milk for breakfast over a 2 week period and was asked to rate the occurrence and severity of bloating, abdominal pain / cramps and rectal gas distension during the 24-h period after each meal. The severity of symptoms was assessed on a 6-point scale (0-no symptoms, 1-trivial symptoms and up to 5-severe symptoms). Twenty-one (70%) patients were considered to have lactose malabsorbtion based on the results of lactose H2-BT (i.e. exhaled H2 concentration raise >10ppm following the ingestion of 15g lactose) while the others were classified as lactose-absorbers. Reviewing the diaries of these patients the authors noticed no difference in the severity of symptoms when patients consumed regular milk and lactose-hydrolyzed milk and no difference between the lactose-absorber and lactosemalabsorber group. Furthermore, although patients believed they were severely lactose intolerant the mean symptom scores recorded in their diaries were in trivialmild range. These data suggest that even patients who consider themselves severely lactose intolerant can tolerate up to one glass (240ml) of milk a day.
The current study has some limitations. The positive and negative predictive values for individual symptoms and their combination depend on the prevalence of lactase deficiency in the examined population. Thus, these values should be interpreted with caution outside Central Europe. Nevertheless, in our study we calculated the respective likelihood ratio that allow to apply results to different prevalence scenarios.
Although data were collected prospectively, we do not have clinical follow-up data to test the appropriateness of the proposed approach for patients who developed symptoms after the ingestion of lactose intolerance. A prospective trial to evaluate the validity and acceptance of the clinical lactose challenge needs to be performed.
Last but not least, since patients included in the present study were patients referred for H2 breath testing, a certain selection bias might be present. Thus, caution is advised when extrapolating present data to the general population but data would be applicable for patients suspected of having lactose intolerance.
Gelöscht: In addition, costeffectiveness analysis is required to estimate the benefit of our recommended approach.
In conclusion, the results of the present study offer the basis for developing a simple clinical lactose tolerance test aimed at screening patients who require further testing for hypolactasia. 
